STOP petitions government to add cronobacter to Nationally Notifiable Disease List

This week there were three hearings in Washington D.C. addressing the infant formula shortage and the reasons behind it. FDA officials were pressed about the failure of leadership and disorganization of the recall by Abbott Nutrition. The FDA refused to take food safety seriously and now the most vulnerable are at risk.

Abbott received 17 consumer complaints between 2019 and 2021. This included 15 complaints of infants testing positive for another pathogen and one complaint related to Cronobacter. The company also found Cronobacter in two batches of formula. The first just one day after an FDA inspection in 2019 in addition to five other environmental samples between 2019 and 2021.

The Abbott recall could have been prevented. The agency had reports of safety failures months before the contaminated formula sickened babies and caused two deaths. Now, infants are going hungry due to the delay and lack of urgency.

Sign the petition now to help us add Cronobacter Sakazakii to the Nationally Notifiable Disease List to prevent this from happening again.

(To sign up for a free subscription to Food Safety News, click here)

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
Bachem wants to expand production significantly +++ Art Basel starts with sales in the millions thumbnail

Bachem wants to expand production significantly +++ Art Basel starts with sales in the millions

Steuerbetrug bei Schweizer UBS? Gericht urteilt am Montag in Berufungsprozess Das Logo der UBS auf einer Filiale in Zürich. Arnd Wiegmann / Reuters(dpa) Den Schweizer Bankriesen UBS erwartet im neu aufgerollten Prozess um mutmasslichen Steuerbetrug in Frankreich eine Entscheidung des Gerichts und möglicherweise eine Milliardenstrafe. Am Montag (13 Uhr 30) will das Pariser Berufungsgericht sein…
Read More

Rosuvastatin Again Linked With Risks to Kidneys

Rosuvastatin for cholesterol lowering was associated with slightly greater risks for kidney harm than atorvastatin, risks that were greater at higher-dose levels, in a large retrospective cohort study. The most potent statin on the market, rosuvastatin has been linked with excess risk for kidney damage compared with atorvastatin in case reports and small trials, but there…
Read More
Index Of News
Total
0
Share